🐦 推特Wall St EngineDoubao · 实盘不做把握 5/10不做原因:其他
北京时间·🕒 发布 18:46:30·⟳ 抓取 18:46:40 +10s·⚡ 决策 10-22 18:49:18 +2m38s·5.2 天前
Quest Diagnostics Q3'26业绩全面超预期并上调全年指引，盘前股价异动但流动性极差
营收/EPS双超预期且上调全年指引，申请单量+14.5%显示需求强劲，属正向surprise；但单申请收入-4.2%构成质量瑕疵、股价处52周高位且盘前报价失真，故以小仓、严格限价、窄涨幅参与，开盘高开过多则放弃
📄 原文Wall St Engine@wallstengine↗ 原文
QUEST DIAGNOSTICS $DGX Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $3.10B (Est. $3.05B) 🟢; +10.0% YoY 🔹 Adj. EPS: $3.00 (Est.…
不做 Quest Diagnostics（DGX.US）
[契约校验:LIMIT_AND_CHASE] entry: limit_price 与 max_chase_pct 只能二选一(给了 limit_price 就把 max_chase_pct 置空) 原交易逻辑:Q3双超预期+上调全年指引，限价低吸不追高
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Quest Q3量价表现为量强价弱：营收/EPS双超预期并上调全年指引，需求端（申请单量+14.5%）强劲，但单申请收入-4.2%压制业绩质量叙事；盘前-6.8%仅291股、价差极大，报价不可信，以小仓限价低吸而非追高
消息传播链
- 节点
关键理由
- 营收31.0亿vs预期30.5亿、调整后EPS 3.00 vs预期2.86，并上调FY26营收至120.7-121.1亿、EPS至11.25-11.35，正向预期差明确
- 申请单量同比+14.5%显示检测需求加速，规模驱动调整后营业利润率达16.7%
主要风险
- 单申请收入同比-4.2%，若电话会强调价格/医保组合逆风，可能出现sell-the-news
- 当前股价距52周高点仅3.6%、PE约27倍，beat-and-raise可能已部分定价；盘前异常低价若开盘证实为真实抛压则不成交并放弃
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
帖文本身披露单申请收入-4.2%，为最明确的反向质量信号；搜索尚未见做空报告、指引下修或客户流失等硬利空，弱于正向surprise
检索:Quest Diagnostics Q3 2026 revenue per requisition decline pricing pressure guidance quality 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足直接反映为small仓位、保守tp与严格限价，而非放弃正向催化
方向:未取得满足首发锚定要求的同市场历史业绩先例，方向不依据先例外推
涨幅量级:高相似aligned先例不足，不据此设定大幅目标，止盈取保守小档[4%,7%]
形态:无法从本轮证据确认大型医检公司beat-and-raise是否反复高开低走，故收紧买点（限价+1.5%）并降为small仓
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 6,457 ms
{"result": "search_processed_events:agent query=`dgx q3 26 results requisition volume | quest diagnostics dgx q3 2026 earnings revenue eps raised guidance | quest diagnostics fy26 guidance raise apple health biomarkers`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26078 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent quer - stock_quote 成功 stock_tools HTTP · 1,470 ms
{ - web_search 成功 doubao_search · 1,608 ms
豆包搜索结果（原始查询:Quest Diagnostics Q3 2026 earnings results raised guidance stock reaction；API SearchType:web） - web_search 成功 doubao_search · 1,949 ms
豆包搜索结果（原始查询:Quest Diagnostics DGX third quarter 2026 revenue per requisition decline premarket；API SearchType:web） - web_search 成功 doubao_search · 1,472 ms
豆包搜索结果（原始查询:"Quest Diagnostics" "Third Quarter 2026" financial results raises guidance October 22；API SearchType:web）
原文全文
展开原文 · 1,165 字
QUEST DIAGNOSTICS $DGX Q3’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $3.10B (Est. $3.05B) 🟢; +10.0% YoY
🔹 Adj. EPS: $3.00 (Est. $2.86) 🟢; +15.4% YoY
🔹 GAAP EPS: $2.78; +28.7% YoY
Raises FY26 Guide:
🔹 Revenue: $12.07B-$12.11B (Est. $12B) 🟢
🔹 Adj. EPS: $11.25-$11.35 (Est. $11.19) 🟢
🔹 GAAP EPS: $10.21-$10.31
🔹 Operating Cash Flow: ~$1.90B
🔹 Capex: ~$550M
Cash Flow:
🔹 Operating Cash Flow: $611M; +8.8% YoY
🔹 Capex: $166M; +15.0% YoY
Other Q3 Metrics:
🔹 Adj. Oper Income: $517M (Est. $487M) 🟢
🔹 Adj. Oper Margin: 16.7%
🔹 Requisition Volume: +14.5% YoY
🔹 Organic Requisition Volume: +14.4% YoY
🔹 Revenue per Requisition: -4.2% YoY
Announcements:
🔹 Quest laboratory test panels with over 50 biomarkers will be available through Apple Health later this year
🔹 Definitive agreement to acquire select outreach lab assets from a leading health system in the Northeastern U.S.
🔹 Launched a new AD-Detect test panel with pTau217, amyloid beta and APOE
🔹 Advanced Project Nova to the solutions-build phase; first lab deployment expected in fall 2027
Comments:
🔸 “With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”
🔹 Revenue: $3.10B (Est. $3.05B) 🟢; +10.0% YoY
🔹 Adj. EPS: $3.00 (Est. $2.86) 🟢; +15.4% YoY
🔹 GAAP EPS: $2.78; +28.7% YoY
Raises FY26 Guide:
🔹 Revenue: $12.07B-$12.11B (Est. $12B) 🟢
🔹 Adj. EPS: $11.25-$11.35 (Est. $11.19) 🟢
🔹 GAAP EPS: $10.21-$10.31
🔹 Operating Cash Flow: ~$1.90B
🔹 Capex: ~$550M
Cash Flow:
🔹 Operating Cash Flow: $611M; +8.8% YoY
🔹 Capex: $166M; +15.0% YoY
Other Q3 Metrics:
🔹 Adj. Oper Income: $517M (Est. $487M) 🟢
🔹 Adj. Oper Margin: 16.7%
🔹 Requisition Volume: +14.5% YoY
🔹 Organic Requisition Volume: +14.4% YoY
🔹 Revenue per Requisition: -4.2% YoY
Announcements:
🔹 Quest laboratory test panels with over 50 biomarkers will be available through Apple Health later this year
🔹 Definitive agreement to acquire select outreach lab assets from a leading health system in the Northeastern U.S.
🔹 Launched a new AD-Detect test panel with pTau217, amyloid beta and APOE
🔹 Advanced Project Nova to the solutions-build phase; first lab deployment expected in fall 2027
Comments:
🔸 “With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
c521ea94c9· 2026-10-22 18:49 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前